Clinical Trial Update: A Study of Trastuzumab in Combination With Capecitabine and Cisplatin in Patients With Tissue HER2- But Serum HER2+ AGC [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating trastuzumab in combination with capecitabine and cisplatin in patients with tissue HER2-negative but serum HER2-positive gastric or g…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Capecitabine (capecitabine)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Asan Medical Center | Conditions: Gastric or Gastroesophageal Junction(GEJ) Adenocarcinoma | Phase 2 | Status: COMPLETED